Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome - Kiraly, D D; Horn, S R; Van Dam, N T; Costi, S; Schwartz, J; Kim-Schulze, S; Patel, M; Hodes, G E; Russo, S J; Merad, M; Iosifescu, D V; Charney, D S; et al. (Translational psychiatry, 2017)
Keywords: 692/53/2423; 692/699/476/1414; Adult; Behavioral Sciences; Biological Psychology; Case-Control Studies; Chemokines - immunology; Cytokines - immunology; Depressive Disorder, Major - drug therapy; Depressive Disorder, Major - immunology; Depressive Disorder, Treatment-Resistant - drug therapy; Depressive Disorder, Treatment-Resistant - immunology; Excitatory Amino Acid Antagonists - therapeutic use; Female; Fibroblast Growth Factor 2 - immunology; Humans; Inflammation; Infusions, Intravenous; Intercellular Signaling Peptides and Proteins - immunology; Interleukin-1alpha - immunology; Interleukin-1beta - immunology; Interleukin-6 - immunology; Ketamine - therapeutic use; Male; Medicine; Medicine & Public Health; Middle Aged; Neurosciences; Original; original-article; Pharmacotherapy; Prognosis; Psychiatry; Treatment Outcome; Tumor Necrosis Factor-alpha - immunology